[go: up one dir, main page]

IL158808A0 - 5-ht receptor ligands and uses thereof - Google Patents

5-ht receptor ligands and uses thereof

Info

Publication number
IL158808A0
IL158808A0 IL15880802A IL15880802A IL158808A0 IL 158808 A0 IL158808 A0 IL 158808A0 IL 15880802 A IL15880802 A IL 15880802A IL 15880802 A IL15880802 A IL 15880802A IL 158808 A0 IL158808 A0 IL 158808A0
Authority
IL
Israel
Prior art keywords
receptor ligands
ligands
receptor
Prior art date
Application number
IL15880802A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL158808A0 publication Critical patent/IL158808A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15880802A 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof IL158808A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29995301P 2001-06-21 2001-06-21
PCT/IB2002/002261 WO2003000663A1 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof

Publications (1)

Publication Number Publication Date
IL158808A0 true IL158808A0 (en) 2004-05-12

Family

ID=23157027

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15880802A IL158808A0 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof
IL15880702A IL158807A0 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL15880702A IL158807A0 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof

Country Status (39)

Country Link
US (6) US6825198B2 (xx)
EP (2) EP1401819A1 (xx)
JP (2) JP2005501821A (xx)
KR (2) KR100566854B1 (xx)
CN (2) CN1630645A (xx)
AP (1) AP2002002561A0 (xx)
AR (1) AR036095A1 (xx)
AU (1) AU2002309173B2 (xx)
BG (2) BG108495A (xx)
BR (2) BR0210471A (xx)
CA (2) CA2455292A1 (xx)
CR (1) CR7168A (xx)
CZ (2) CZ20033508A3 (xx)
DO (1) DOP2002000412A (xx)
EA (2) EA007183B1 (xx)
EC (2) ECSP034881A (xx)
EE (2) EE200400026A (xx)
GE (1) GEP20053655B (xx)
GT (1) GT200200120A (xx)
HR (1) HRP20031042A2 (xx)
HU (2) HUP0400249A3 (xx)
IL (2) IL158808A0 (xx)
IS (2) IS7040A (xx)
MA (2) MA27036A1 (xx)
MX (2) MXPA03011941A (xx)
NO (2) NO20035697D0 (xx)
NZ (1) NZ529542A (xx)
OA (2) OA12621A (xx)
PA (1) PA8548901A1 (xx)
PE (1) PE20030268A1 (xx)
PL (2) PL367777A1 (xx)
SK (2) SK15712003A3 (xx)
SV (1) SV2003001102A (xx)
TN (2) TNSN03143A1 (xx)
UA (1) UA74443C2 (xx)
UY (1) UY27343A1 (xx)
WO (2) WO2003000663A1 (xx)
YU (1) YU95303A (xx)
ZA (2) ZA200308843B (xx)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
US7226925B2 (en) 2002-06-19 2007-06-05 Biovitrum Ab Compounds, their use and preparation
DE60330864D1 (de) * 2002-06-19 2010-02-25 Biovitrum Ab Publ Neue verbindungen, deren verwendung und herstellung
RS20050532A (xx) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004207675B2 (en) * 2003-01-29 2010-05-20 Asterand Uk Acquisition Limited EP4 receptor antagonists
EA010727B1 (ru) * 2003-02-26 2008-10-30 Суджен, Инк. Аминогетероарильные соединения в качестве ингибиторов протеинкиназ
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US20040235856A1 (en) * 2003-04-25 2004-11-25 Pfizer Inc Treatment of incontinence
US20080146583A1 (en) * 2003-05-15 2008-06-19 Pfizer Inc Treatment of Incontinence
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
CN101274911B (zh) 2003-06-17 2011-01-26 艾尼纳制药公司 用于治疗5ht2c受体相关病症的苯并氮杂卓衍生物
EP2189448B1 (en) 2003-06-17 2014-01-29 Arena Pharmaceuticals, Inc. Processes for the Separation of 3-Benzazepine Racemates
CN1809545A (zh) * 2003-06-20 2006-07-26 艾尼纳制药公司 N－苯基－哌嗪衍生物和预防或者治疗5HT2c受体相关疾病的方法
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
AU2004278382B2 (en) * 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US20080194574A1 (en) * 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
ATE415397T1 (de) * 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
US8114502B2 (en) * 2004-09-02 2012-02-14 3M Innovative Properties Company Substrates with multiple images
EP2286838A3 (en) * 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
AU2005305036B2 (en) * 2004-11-01 2011-03-10 Amylin Pharmaceuticals, Llc Treatment of obesity and related disorders
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
EP1844792A4 (en) * 2004-12-14 2008-05-21 Shionogi & Co THERAPEUTIC AGENT AGAINST OBSTIPATION
EP2327698B1 (en) 2004-12-21 2015-08-05 Arena Pharmaceuticals, Inc. Process for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate
ATE442135T1 (de) * 2004-12-23 2009-09-15 Arena Pharm Inc 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
AU2006209216A1 (en) * 2005-01-25 2006-08-03 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
CA2602348C (en) * 2005-03-31 2011-03-01 Pfizer Products Inc. Cyclopentapyridine and tetrahydroquinoline derivatives
US7594976B2 (en) * 2005-05-13 2009-09-29 3M Innovative Properties Company Methods of manufacturing substrates
EP2324886A1 (en) 2005-07-29 2011-05-25 Concert Pharmaceuticals Inc. Novel deuterated analogues of tadalafil
JP5597353B2 (ja) * 2005-09-30 2014-10-01 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
RU2387650C2 (ru) * 2005-12-05 2010-04-27 Пфайзер Продактс Инк. Полиморфы с-met/hgfr ингибитора
ATE488237T1 (de) * 2005-12-05 2010-12-15 Pfizer Prod Inc Verfahren zur behandlung von abnormalem zellwachstum
EP1965862A2 (en) * 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
CN101466684B (zh) 2006-04-03 2012-06-20 艾尼纳制药公司 8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的制备工艺和其相关中间体
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
JP2009538859A (ja) * 2006-05-30 2009-11-12 エフ．ホフマン−ラ ロシュ アーゲー ピペリジニルピリミジン誘導体
ATE496894T1 (de) * 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
EP2084127A1 (en) 2006-11-13 2009-08-05 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
WO2008058341A1 (en) 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity
JP5404414B2 (ja) 2006-12-05 2014-01-29 アリーナ ファーマシューティカルズ， インコーポレイテッド （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンおよびその中間体を調製するための方法
DK2118279T3 (en) 2007-01-16 2018-02-26 Ipintl Llc HIS UNKNOWN COMPOSITION FOR TREATMENT OF METABOLIC SYNDROME
US20080220104A1 (en) * 2007-03-08 2008-09-11 Cappello John V Compositions for producing satiety
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2008262291A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
US8822727B2 (en) * 2008-03-04 2014-09-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
MX2010013726A (es) 2008-06-12 2011-01-14 Janssen Pharmaceutica Nv Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina.
US20120094974A1 (en) * 2008-06-17 2012-04-19 Wei Chen Smoothened receptor modulators
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8759539B2 (en) 2008-11-17 2014-06-24 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
EP2443080A2 (en) 2009-06-18 2012-04-25 Arena Pharmaceuticals, Inc. Process for the preparation of 5-ht2c receptor agonists
ES2587064T3 (es) * 2009-06-26 2016-10-20 Sanofi Sales fumarato novedosas de un antagonista del receptor de histamina H3
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US10167305B2 (en) 2010-06-23 2019-01-01 Johnson Matthey Public Limited Company Allyl complexes for use in coupling reactions
EP2611433A2 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
EP2611449A1 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
EP2611782A1 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
US20130315994A1 (en) 2010-09-01 2013-11-28 Zezhi Jesse Shao Modified-release dosage forms of 5-ht2c agonists useful for weight management
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
PL2678331T3 (pl) * 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania
MX2014014308A (es) * 2012-05-30 2015-02-12 Hoffmann La Roche Pirrolidino heterociclos.
BR112015002080A2 (pt) 2012-08-02 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
RU2674670C1 (ru) 2012-10-09 2018-12-12 Арена Фармасьютикалз, Инк. Способ коррекции массы тела
JP6387488B2 (ja) 2013-01-10 2018-09-12 プルモキネ、インコーポレイテッド 非選択的キナーゼ阻害剤
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN106132403B (zh) 2013-10-11 2020-04-28 普尔莫凯恩股份有限公司 喷雾干燥制剂
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
UA126268C2 (uk) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
US10231966B2 (en) 2016-10-27 2019-03-19 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
MX2020013157A (es) 2018-06-06 2021-04-29 Arena Pharm Inc Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
CN114025750A (zh) * 2019-03-07 2022-02-08 阿伯门蒂斯有限责任公司 包含神经可塑性作用物质的以非迷幻/致幻觉剂量和制剂给药的组合物和使用方法
CN111704582B (zh) * 2020-06-23 2021-06-11 杭州煌森生物科技有限公司 一种法匹拉韦及其衍生物的制备方法
CN115618396B (zh) * 2022-11-28 2023-04-07 云账户技术(天津)有限公司 一种数据的加密方法及装置

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127996C (xx) * 1963-11-19
US3980781A (en) * 1966-03-31 1976-09-14 Imperial Chemical Industries Limited Fungicidal composition and method containing 2-amino-pyrimidines
GB1165283A (en) * 1967-01-17 1969-09-24 Science Union & Cie New Purine Derivatives and processes for prepararing them
US4166852A (en) * 1974-08-09 1979-09-04 Produits Chimiques Ugine Kuhlmann Piperazino-pyrimidines and their use as spasmolytic agents
FR2281117A2 (fr) 1974-08-09 1976-03-05 Ugine Kuhlmann Nouvelles piperazino-pyrimidines utilisables comme medicaments
US4081542A (en) * 1975-04-21 1978-03-28 Merck & Co., Inc. Piperazinylpyrazines
EG12387A (en) * 1975-04-21 1978-12-31 Merck & Co Inc Process for preparing of piperazinyl pyrazines
FR2311776A1 (fr) * 1975-05-23 1976-12-17 Sogeras Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation
FI70411C (fi) * 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
JPH0665203A (ja) * 1992-06-25 1994-03-08 Elf Sanofi ピペラジンのヘテロ環誘導体
JP2789134B2 (ja) 1992-09-28 1998-08-20 ファイザー・インク． 糖尿病の合併症を制御する置換ピリミジン類
HUT74464A (en) * 1993-10-12 1996-12-30 Du Pont Merck Pharma 1n-alkyl-n-arylpyrimidinamines and derivatives thereof, and pharmaceutical compositions containing them
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
US5419301A (en) * 1994-04-14 1995-05-30 Ford Motor Company Adaptive control of camless valvetrain
CA2217034A1 (en) * 1995-04-03 1996-10-10 Sumitomo Pharmaceuticals Company, Limited Novel pyrimidine derivatives effective as psychotropic drug and process for the production thereof
US5795905A (en) 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
PT791355E (pt) * 1996-02-29 2002-08-30 Pfizer Metodo para diminuir os daos associados com a isquemia nos tecidos
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
KR100239800B1 (ko) * 1996-11-28 2000-03-02 손경식 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
WO2000028993A1 (en) 1998-11-19 2000-05-25 Nortran Pharmaceuticals, Inc. Serotonin ligands as pro-erectile compounds
GB9902047D0 (en) 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
AU777276C (en) 1999-05-21 2005-07-07 Biovitrum Ab Novel compounds, their use and preparation
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
JP4204315B2 (ja) 2000-11-20 2009-01-07 ビオヴィトルム・アクチボラゲット（プブリクト） セロトニン５−ｈｔ２レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
MXPA03004390A (es) 2000-11-20 2004-05-14 Biovitrum Ab Compuestos de piperazinilpirazina utiles como un agonista o antagonista del receptor 5ht-2 de serotonina.
SE0004245D0 (sv) * 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use

Also Published As

Publication number Publication date
US20050054656A1 (en) 2005-03-10
HUP0400251A2 (hu) 2004-08-30
UA74443C2 (uk) 2005-12-15
KR100566854B1 (ko) 2006-04-03
OA12629A (en) 2006-06-14
IS7040A (is) 2003-11-17
US20050020604A1 (en) 2005-01-27
ECSP034884A (es) 2004-01-28
US20050032809A1 (en) 2005-02-10
US6894050B2 (en) 2005-05-17
YU95303A (sh) 2006-08-17
KR20040010765A (ko) 2004-01-31
EP1401820A1 (en) 2004-03-31
KR20040010767A (ko) 2004-01-31
GEP20053655B (en) 2005-11-10
EP1401819A1 (en) 2004-03-31
CA2450491A1 (en) 2003-01-03
HRP20031042A2 (en) 2005-10-31
TNSN03142A1 (fr) 2005-12-23
US20050090503A1 (en) 2005-04-28
IS7041A (is) 2003-11-17
ZA200308843B (en) 2004-11-23
AR036095A1 (es) 2004-08-11
MA27035A1 (fr) 2004-12-20
AU2002309173B2 (en) 2007-04-26
US20030125334A1 (en) 2003-07-03
JP2005501821A (ja) 2005-01-20
NO20035698D0 (no) 2003-12-19
HUP0400251A3 (en) 2006-02-28
DOP2002000412A (es) 2002-12-30
US6995159B2 (en) 2006-02-07
US6825198B2 (en) 2004-11-30
CN1745074A (zh) 2006-03-08
MXPA03011940A (es) 2004-03-26
CZ20033431A3 (en) 2004-07-14
ECSP034881A (es) 2004-01-28
CR7168A (es) 2004-02-23
BG108495A (en) 2004-08-31
PL367746A1 (en) 2005-03-07
WO2003000663A1 (en) 2003-01-03
BR0210471A (pt) 2004-08-10
HUP0400249A2 (hu) 2004-08-30
WO2003000666A1 (en) 2003-01-03
EE200400025A (et) 2004-06-15
BR0210503A (pt) 2004-05-18
ZA200308842B (en) 2004-11-23
OA12621A (en) 2006-06-12
CZ20033508A3 (en) 2004-05-12
NO20035697D0 (no) 2003-12-19
EE200400026A (et) 2004-06-15
PA8548901A1 (es) 2003-02-14
US20030105106A1 (en) 2003-06-05
CA2455292A1 (en) 2003-01-03
BG108491A (en) 2005-01-31
HUP0400249A3 (en) 2009-01-28
GT200200120A (es) 2003-02-13
NZ529542A (en) 2005-05-27
TNSN03143A1 (fr) 2005-12-23
PL367777A1 (en) 2005-03-07
EA007183B1 (ru) 2006-08-25
MA27036A1 (fr) 2004-12-20
PE20030268A1 (es) 2003-03-19
AP2002002561A0 (en) 2002-06-30
EA200301215A1 (ru) 2004-04-29
JP2004534823A (ja) 2004-11-18
SK15712003A3 (sk) 2004-06-08
EA200301213A1 (ru) 2004-06-24
CN1630645A (zh) 2005-06-22
SK15672003A3 (sk) 2004-05-04
MXPA03011941A (es) 2004-03-26
NO20035698L (no) 2004-02-17
SV2003001102A (es) 2003-03-18
IL158807A0 (en) 2004-05-12
UY27343A1 (es) 2003-02-28

Similar Documents

Publication Publication Date Title
IL158808A0 (en) 5-ht receptor ligands and uses thereof
ZA200507350B (en) Cannabinoid receptor ligands and uses thereof
IL172026A0 (en) Cannabinoid receptor ligands and uses thereof
IL161439A0 (en) Cannabinoid receptor ligands
IL156829A0 (en) Cannabinoid receptor ligands
GB0214835D0 (en) Suspended seat
IL157969A0 (en) Melanocortin receptor ligands
IL173265A0 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazcpine receptor ligands
PL354799A1 (en) Complex containing ocif and polysaccharide
AU2002346507A8 (en) Benzazepine derivatives and their use as 5-ht ligands
GB0106434D0 (en) Novel estrogwen receptor ligands and methods II
GB2378645B (en) Seat
GB0100163D0 (en) Novel estrogen receptor ligands and methods
GB0124346D0 (en) Receptor and its use
GB0110662D0 (en) Receptor
GB0111959D0 (en) Receptor
GB0114929D0 (en) Receptor
GB0125183D0 (en) Receptor
GB0128161D0 (en) Receptor protein
AU146542S (en) Hanging seat
GB2378644B (en) Seat
GB0211204D0 (en) Receptor and its ligand
CA96919S (en) Spout
GB2371220B (en) Hanger
TW499932U (en) Double-bag-type pillow